Dr. Yang is the Chairman and Co-Founder of Acepodia. Dr. Yang was formerly Executive Vice President at Juno Therapeutics. Prior to Juno, he served as Executive Vice President of Technical Operations at Roche and Genentech, where he was responsible for biopharmaceutical manufacturing, process development, engineering, technical regulatory, quality, procurement, and global supply chain management. Prior to Genentech, he served in various leadership roles in the industry with Merck, General Electric and Life Systems. Dr. Yang earned his B.S. in Engineering from National Chiao Tung University (Taiwan), his M.S. from the University of Cincinnati, and his Ph.D. in Engineering from Ohio State University.

Dr. Hsiao is the Chief Executive Officer, President and Co-Founder of Acepodia. He was awarded Dr. Y-T Lee Prize, which named after Nobel Laureate Dr. Lee, for his research achievement in Chemistry. Dr. Hsiao has extensive research experience in immune cell therapy development, which led to the discovery and invention of Acepodia’s novel cellular immunotherapy development platform, ACC (Antibody-Cell Conjugation). Dr. Hsiao earned his B.S. in Chemistry from National Taiwan University, and his Ph.D. in Chemistry and Molecular Cell Biology from the University of California, Berkeley.

Dr. Gilbert has decades of experience leading strategic drug development and portfolio management in medical oncology for several U.S. biotech and pharmaceutical companies. He was previously the chief medical officer of Juno Therapeutics, where he led the clinical development of its CAR-T cell therapy pipeline, and previously held similar positions at Bayer Schering Pharmaceuticals, Berlex Pharmaceuticals and its parent company Schering, AG, and Immunex. Dr. Gilbert received a B.S. in Biochemistry from the University of Iowa and his M.D. from the University of Iowa Medical School. He trained in internal medicine, infectious disease and medical oncology at the University of California, San Francisco, and the University of Washington, respectively. Prior to his executive industry positions, Dr. Gilbert was a faculty member at the Fred Hutchinson Cancer Research Center and the University of Washington, and he trained in the laboratory of Dr. Phil Greenberg, one of scientific co-founders of Juno Therapeutics.

Dr. McCracken has more than 25 years of experience in research, strategic business development and commercial roles in biotechnology and pharmaceutical companies. He was previously vice president and global head of business development and licensing for Roche Pharma, where he was responsible for Roche Pharma’s global in-licensing and out-licensing activities. Prior to joining Roche Pharma, Dr. McCracken held the position of vice president of business development at Genentech for more than nine years, and previously held similar positions at Aventis Pharma and Rhone-Poulenc Rorer. Dr. McCracken holds a B.S. in Microbiology, a M.S. in Pharmacology, and a D.V.M. from Ohio State University. 

As a seasoned drug development and regulatory affairs expert with over 25 years in the biopharmaceutical industry, Dr. Mackin has held senior leadership positions in regulatory and manufacturing functions within a number of biopharmaceutical companies and consultant agencies, including Aptuit Consulting. Dr. Mackin received his B.S. in Biology and Microbiology from University of Illinois at Urbana-Champaign, and Ph.D. in Microbiology and Immunology from University of Illinois at Chicago. Dr. Mackin was a post-doctoral fellow at University of Connecticut Health Center. Dr. Mackin also currently serves as President of WMackin & Associates.

Dr. Kurman has spent over thirty years in the oncology drug development field. He is a board-certified medical oncologist who practiced community oncology and has participated as an investigator in oncology clinical trials sponsored by the Eastern Cooperative Oncology Group (ECOG) and the Memorial Adjunct Staff Oncology Group (MASOG). During his career in the pharmaceutical industry, he has held positions of progressive responsibility at Janssen Pharmaceutica as Director of Oncology, and has held similar positions at Cytogen Corporation, U.S. Bioscience, and Quintiles’ (now IQVIA) Oncology Therapeutics Division. During his career in the pharmaceutical industry, Dr. Kurman has been involved in the regulatory review or commercial launch of four new oncology products. Dr. Kurman received his B.A., summa cum laude in biology from Syracuse University and his M.D. from Cornell University Medical College. He received his training in internal medicine at the State University of New York – Upstate Medical Center, and his oncology training at Mt. Sinai Medical Center in New York. 

Dr. Yang is the Chairman and Co-Founder of Acepodia. Dr. Yang was formerly Executive Vice President at Juno Therapeutics. Prior to Juno, he served as Executive Vice President of Technical Operations at Roche and Genentech, where he was responsible for biopharmaceutical manufacturing, process development, engineering, technical regulatory, quality, procurement, and global supply chain management. Prior to Genentech, he served in various leadership roles in the industry with Merck, General Electric and Life Systems. Dr. Yang earned his B.S. in Engineering from National Chiao Tung University (Taiwan), his M.S. from the University of Cincinnati, and his Ph.D. in Engineering from Ohio State University.

Dr. Hsiao is the Chief Executive Officer, President and Co-Founder of Acepodia. He was awarded Dr. Y-T Lee Prize, which named after Nobel Laureate Dr. Lee, for his research achievement in Chemistry. Dr. Hsiao has extensive research experience in immune cell therapy development, which led to the discovery and invention of Acepodia’s novel cellular immunotherapy development platform, ACC (Antibody-Cell Conjugation). Dr. Hsiao earned his B.S. in Chemistry from National Taiwan University, and his Ph.D. in Chemistry and Molecular Cell Biology from the University of California, Berkeley.

Dr. Yang has many years of experience working in various operations of the global pharmaceutical and biotech industry. She has held management and analytical positions in market analysis at Merck, Genentech and Roche. The most recent position was serving as a VP of business operations for a start-up company. Dr. Yang is an expert in market research, market strategy development, and big data analysis. She received a M.S. from Ohio University and a Ph.D. from Ohio State University.

Dr. Chang is Chairman and CEO of YFY Biotech Management Company and is an adjunct professor at the Institute of Public Health at National Yang-Ming University. Prior to joining YFY Group, Dr. Chang held several key positions in the Taiwanese Ministry of Health and served as President and CEO at the Bureau of National Health Insurance (BNHI) and has extensive experiences in health care and disease control. During Dr. Chang’s tenure at BNHI, he established the Smart Card System for every citizen’s access to health care. Dr. Chang earned his M.D. from National Yang-Ming University and he also received his M.P.H. from National Taiwan University and M.S. in Health Policy and Management from Harvard School of Public Health.

Center Ventures, based in Taipei, Taiwan, is a pharmaceutical and biotechnology incubator platform company originally founded in 1959 as a pharmaceutical company. Since its founding, the company has grown to work with companies in the biotechnology industry chain, including small molecule drug R&D, protein and antibody development, pharmaceutical CDMO, pharmaceutical manufacturing and sales, medical devices, nutritional health and agricultural biotechnology, emerging medicine (stem cell and immune cell therapy), and industry investment fund and venture capital. With more than seventy years of practical experience and business expertise in biotechnology, Center Ventures supports high potential companies to address unmet medical needs. The company has invested in more than twenty biotech companies, eight of which have been successfully listed on the stock market. In 2017, Center Ventures financially backed Acepodia to develop its proprietary antibody-conjugated cells to help eradicate cancer.
For more information please visit: https://www.centerventures.com.tw/en

China Investment & Development Consultants (CIDC) is a venture capital consulting firm founded in 1988 in Taipei, Taiwan. CIDC fields a powerful team of shareholders, including Tasco Chemical Corporation, Chiao Tung Bank, Formosa Plastics, Far Eastern Textiles, Yuen Foong Yu, Tung Ho Steel, He-xin Investment, and Tailung Industrial and is placing equal investment emphasis on both biotech industry and the electronics/IT industry. The company manages three investment funds, with assets under its management totaling NTD$6.3 billion and is in the process of raising capital for its fourth fund. CIDC has invested in 330 domestic and foreign companies, one third of which have executed a successful IPO, accounting for NTD$6 billion in returns.
For more information please visit: http://www.gih.com.tw/eng/cidc/index.htm

Top Taiwan Venture Capital (TTVC) was established in 1999 and is one of the largest and leading venture capital management companies in Taiwan. The shareholders of TTVC consist of fourteen Taiwanese insurance companies and eleven Taiwanese Securities Companies. Managing more than NTD$12 billion, TTVC’s investing field covers industries such as technology, biotechnology, renewable energy, consumer retail, food and beverages, healthcare, and auto parts and their investing activities rang from pre-IPO and growth investment to post-IPO stock and convertible bond investments. Having twenty years of experience in Greater China, TTVC has invested in more than 250 successful companies and has been continuously offering long-term capital commitment and support to their invested companies.
For more information please visit: http://www.toptaiwan.com.tw/topen/

Dr. Fyfe has more than 20 years of drug development experience in oncology and currently serves as a board member of Molecular Partners AG. Prior to joining Molecular partners AG, she had held various position at Genentech Inc. and played an important role in the development of Genentech’s approved oncology agents including Rituxan®, Herceptin®, Avastin® and Tarceva®. Dr. Fyfe is a recognized expert in the broader oncology community and has been an invited member of Institute of Medicine panels, National Cancer Institute working groups and grant committees and American Society of Clinical Oncologists oversight committees. Dr. Fyfe is a graduate of Washington University School of Medicine and a board-certified pediatric oncologist.

Dr. Yu is Distinguished Chair Professor and Co-Director of the Institute of Stem Cell and Translational Cancer Research at Chang Gung University (Taiwan). She is also the Academician and Visiting Research Fellow of the Genomic Research Center at Academia Sinica (Taiwan), Professor in Pediatrics and Pediatric Hematology and Oncology at the University of California, San Diego. Dr. Yu earned her medical degree from the National Taiwan University, her M.S. from Yale University, and her Ph.D. in Microbiology and Immunology from University of Chicago.

Dr. Yeh is former CEO and founder of PharmaEngine, where she led the company to develop its oncology product, Onivyde®, approved by U.S. FDA approval in 2015 as a treatment for advanced pancreatic cancer. Prior to founding PharmaEngine, she served in senior positions at Millennium Pharmaceuticals, LeukoSite, CytoMed, and T Cell Sciences, all based in Cambridge, MA, USA. Dr. Yeh received the Go-Global gold medal for PEP02 project (Onivyde) at the 2016 Taipei Biotech Award and was named EY Entrepreneur of the Year in 2016. Dr. Yeh received her B.S. in Biology from Fu-Jen University, Taiwan, and her Ph.D. in Immunology from Medical University of South Carolina.

Dr. Meyer is an assistant professor of Medicine and of Pediatrics at Stanford University Medical Center. His research focuses on T-cells and invariant NKT cells facilitation of immune tolerance and graft-versus-leukemia effects in the setting of hematopoietic cell transplantation. Dr. Meyer received his B.S. from Yale University, M.S. in molecular evolution from Stanford University and a combined M.D./ Ph.D. degree from Stanford Medical School.

Dr. Ho serves as adjunct Ludwig scientist and associate professor in the Department of Oncology at the University of Lausanne. Dr. Ho’s research focuses on immunometabolism in T cells and macrophages, and how the metabolic crosstalk between cancer cells and tumor-infiltrating immune cells shapes the immunosuppressive microenvironment. His team leverages this knowledge to develop cancer immunotherapy. Dr. Ho has been awarded the Swiss Bridge Award, Anna Fuller Award, Cancer Research Institute-CLIP investigator award, Melanoma Research Alliance-SITC Young investigator Award and a European Research Council Starting Grant. Dr. Ho received his M.S. degree from the Institute of Biochemical Science at National Taiwan University and his Ph.D. from the Department of Pharmacology at the University of Minnesota.

Dr. Chen is a clinician at the Department of Oncology, Taipei Veterans General Hospital. Dr. Chen has extensive experience in research and development of immunotherapies in solid tumors and has overseen numerous successful enrollment efforts in several major pivotal immunotherapy trials in liver cancer. Dr. Chen received his M.D. from Taipei Medical University.

Mr. Akira Matsuno is an experienced entrepreneurial biotech executive. He served as the CFO and Head of Corporate Development at Lyell Immunopharma. Prior to Lyell, he was Vice President of Finance and NEX-T Platform Program Lead for Juno Therapeutics, supporting the merging of Juno with Celgene following Juno’s acquisition. Mr. Matsuno started his career at Lehman Brothers after he earned his B.S. in Finance and Management from the Wharton School of University of Pennsylvania.

Dr. Lam is Executive Vice President of Technical Operations at JW Therapeutics.  Previously, he was Head of Therapeutic Technical Operations at 23andMe, Vice President and Head of Manufacturing at Sanofi and Shire Regenerative Medicine. Prior to Sanofi and Shire, he worked in various leadership roles in CMC and manufacturing engineering at Genentech-Roche. Dr. Lam received his B.S. in Chemical Engineering from the University of Birmingham, and his Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute.

Dr. Yu-Shiang Chang is a clinician at Tai-Cheng Cell Therapy Center, National Taiwan University Cancer Center. Besides practicing medicine in hematology and oncology, Dr. Chang leads research efforts focusing on the development of the next generation of cellular immunotherapies. He received his M.D. from China Medical University and Ph.D. from National Sun Yat-sen University. Dr. Chang was the postdoctoral fellow at the National University Hospital in Singapore, and St. Jude Children's Research Hospital in Tennessee.

Dr. Gau led the Center of Drug Evaluation (CDE) as Executive Director to assist Department of Health (DOH, now MOHW) in Taiwan on the technical evaluation for market approval of drugs and medical devices. Prior to joining CDE, she served for DOH as an expert in many committees, specializing in the evaluation of new drug application and assessment of drug safety. Dr. Gau received her Ph.D. in Pharmaceutics from the School of Pharmacy at University of Wisconsin-Madison.